@article{JTD13541,
author = {Yun-Yan Dai and Hai-Shan Zhang and Xin-Gang Zhang and Qi-Gang Guan and Yuan Gao and Yu-Ze Li and Yue-Lan Zhang and Da-Lin Jia and Ying-Xian Sun and Guo-Xian Qi and Wen Tian},
title = {Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {5},
year = {2017},
keywords = {},
abstract = {Background: Studies comparing the clinical efficacy and safety of intensive statin therapy with ezetimibe-statin combination therapy are still rare at present, especially in Asian population.
Methods: We enrolled 202 patients who suffered acute coronary syndrome (ACS) and underwent percutaneous coronary intervention (PCI) between May and July in 2016. Patients were allocated into three groups based on the lipid lowering strategy: moderate-intensity statin group (n=118), ezetimibe combined with moderate-intensity statin group (ezetimibe-statin combination, n=55) and intensive statin group (n=29). The lipid profiles and side effects were analyzed and compared among the patients in three groups at admission, 1 month and 3 months after PCI. The clinical outcomes of the patients were observed through 6-month follow-up.
Results: One month after PCI, the level of non-high density lipoprotein-cholesterol (non-HDL-C) was decreased by 41.9%, 21.6% and 29.8% by ezetimibe-statin combination therapy, moderate-intensity statin therapy and intensive statin therapy, respectively (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/13541}
}